Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
14.654 / 17.019
#117225

Re: Farmas USA

FGEN

Buenas noticias aparentemente. Comparable a placebo. He comprado antes 10 cromos. Había buenas opciones de que fuera positivo pero no me he atrevido a tener más de 30 cromos para el evento...

https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease.html
#117226

Re: Farmas USA

FGEN
Tiene pinta de buena castaña.
#117227

Re: Farmas USA

TEVA 
He vendido un pak, como el 40% para tener números redondos. Por 9,17 ha entrado. Un piko xq las tenía 8,6 (sin contar primas) 

Eso si, es un enguaje por que ahora les deje unas vputs si recae en su costumbre de aflojar/abrir cortos (eso si, para recuperar las a un precio parecido con la prima semanal) 

Rollo estar fuera y ver de reojo
#117228

Re: Farmas USA

FGEN noticia 19:45
 

 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN 

NEW YORK, NY / ACCESSWIRE / November 8, 2019 / Pomerantz LLP is investigating
claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")
(NASDAQ:FGEN). Such investors are advised to contact Robert S. Willoughby at
[email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether FibroGen and certain of its officers and/or
directors have engaged in securities fraud or other unlawful business
practices.

[Click here for information about joining the class action]
(https://form.jotform.com/pomerantzllp2/FGEN)

On November 4, 2019, Plainview LLC ("Plainview") published a report
questioning the safety of Fibrogen's lead product candidate, Roxadustat, and
describing the Company as the next "biotech blow-up." The Plainview report
asserted that the FibroGen was "mysteriously unforthcoming" and misleading
investors with regards to the safety and efficacy of Roxadustat.

On this news, Fibrogen's stock price fell $3.01 per share, or 7.52%, to close
at $37.01 per share on November 4, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 80 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP
View source version on accesswire.com:
https://www.accesswire.com/565880/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-FibroGen-Inc--FGEN


Copyright 2019 ACCESSWIRE. All Rights Reserved.

Rango : negativo 
#117230

Re: Farmas USA

FGEN

Castaña? Los datos que he visto parecen muy buenos. Abre con +17% (más de +25% desde antes de cerrar).
#117231

Re: Farmas USA

FGEN
Cerrada posición y a la saca.
Por 5 pavos no merece esperar una semana.
Fenomenal.
#117232

Re: Farmas USA

TEVA me las he quitado por higiene mental ....no quiero más sustos este año , y he asegurado el cerrar en + en 2019..que si contara la pasta que perdí con la venta de las put.....DIA en marzo ....🙄....es todo un éxito  .....que volveré a entrar es casi seguro , pero de momento no ...ojalá siga subiendo para bien de los que siguen dentro , pero un servidor observará desde la barrera a la espera de una mejor opción ....